Jaguar Health, Inc. (JAGX) analyst actions
JAGX analyst actions moved a median of -3.43% by the close. Rating and price-target actions on JAGX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the JAGX overview →
11 measured JAGX analyst action events.
| Middle 50% of JAGX analyst action reactions | -5.73% to -1.85% |
|---|---|
| Median reaction (to close) | -3.43% |
| Measured reactions | 11 |
Half of the 11 JAGX analyst action events with a measured close landed between -5.73% and -1.85%; 9% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs | Press release | -3.01% | -1.14% | |
| Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression | Press release | -2.75% | -4.30% | |
| Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) | Press release | -0.36% | -15.00% | |
| Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | Press release | +1.90% | +0.00% | |
| Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 | Press release | -0.66% | -4.63% | |
| Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025 | Press release | -1.50% | -2.57% | |
| Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder | Press release | -1.42% | -6.84% | |
| U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins | Press release | +0.00% | -3.43% | |
| Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting | Press release | -2.03% | -3.25% | |
| Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea | Press release | -6.09% | -15.34% | |
| Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications | Press release | -0.40% | +1.49% |
More JAGX: earnings → · SEC filings → · JAGX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Arvinas, Inc. (ARVN) | 442 | -0.26% | 42% |
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.